Generex Biotechnology Announces First Patient Enrolled in the Phase II Clinical Trial of AE37 in Combination with Pembrolizumab (KeytrudaÒ) for the Treatment of Triple Negative Breast Cancer

    NEXT STORY
    INmune Bio Invited to Speak on Company’s Advancements in Cancer Treatments at the Targeting Innate Immunity Congress and MarketsandMarkets Next Gen Immuno-Oncology Congress
    PREV STORY
    Helsinn and Lyfebulb Announce Call for Applications for Third Annual Patient-Driven Innovation Summit & Award in Oncology
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Nuance Expands Vision and Capabilities for Next Generation AI Powered Virtual Assistants for Healthcare

    Company showcases unified vision for ambient clinical documentation and announces general availability of virtual ...

    author_avatar
    NASDAQ Market News

    GCC $1.83 Billion In-Vitro Diagnostic Devices Market to 2023

    Dublin, Jan. 21, 2019 (GLOBE NEWSWIRE) -- The "GCC In-Vitro Diagnostic Devices Market: Industry ...

    author_avatar
    NASDAQ Market News

    Immunomedics Receives Edison Patent Award From Research & Development Council of New Jersey for the Fourth Time

    MORRIS PLAINS, N.J., Nov. 04, 2016 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU) today announced ...

    author_avatar
    NASDAQ Market News